Treatment patterns in multiple sclerosis: Administrative claims analysis over 10 years

Journal of Medical Economics

Volumn 16, Issue 3, 2013, Pages 397-406

  Oleen Burkey, Merrikay ^a,b   Cyhaniuk, Anissa ^c   Swallow, Eric ^c  

^a Outcomes Scribe   (United States)

^b Teva Pharmaceuticals   (United States)

^c OPTUM   (United States)

Author keywords

Disease modifying therapy; Immunomodulatory therapy; Multiple sclerosis; Treatment patterns

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; NATALIZUMAB;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; INTERMETHOD COMPARISON; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PATIENT IDENTIFICATION; PRESCRIPTION; RETROSPECTIVE STUDY; TREATMENT PATTERN; TREATMENT PLANNING; TREATMENT RESPONSE;

ADOLESCENT; ADULT; DATABASES, FACTUAL; DRUG SUBSTITUTION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INSURANCE CLAIM REVIEW; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PHYSICIAN'S PRACTICE PATTERNS; RETROSPECTIVE STUDIES; UNITED STATES; YOUNG ADULT;

EID: 84873929621     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2013.764309     Document Type: Article

References (19)

1. Compston A, Coles A. Multiple sclerosis. Lancet 2002;359:1221-31
2. National Multiple Sclerosis Society. Epidemiology of MS [online]. National Multiple Sclerosis Society, 2011. http://www.nationalmssociety.org/ about-multiple-sclerosis/what-we-know-about-ms/who-gets-ms/epidemiology-of-ms/ index.aspx. Accessed September 5, 2011.
3. Derwenskus J. Current disease-modifying treatment of multiple sclerosis. Mt Sinai J Med 2011;78:161-75
4. Expert opinion paper: disease management consensus statement [online]. National Clinical Advisory Board of the National Multiple Sclerosis Society 2008, New York, NY. http://www.nationalmssociety.org/search-results/index.aspx? q=ConsensusStatement&start=0&num=20&x=22&y=10. Accessed September 5, 2011.
5. O'Rourke KE, Hutchinson M. Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Mult Scler 2005;11:46-50
6. Río J, Porcel J, Téllez N, et al. Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler 2005;11:306-9
7. Tremlett HL, Oger J. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology 2003;61:551-4
8. Twork S, Nippert I, Scherer P, et al. Immunomodulating drugs in multiple sclerosis: compliance, satisfaction and adverse effects evaluation in a German multiple sclerosis population. Curr Med Res Opin 2007;23:1209-15
9. Reynolds MW, Stephen R, Seaman C, et al. Healthcare resource utilization following switch or discontinuation in multiple sclerosis patients on disease modifying drugs. J Med Econ 2010;13:90-8
10. Reynolds MW, Stephen R, Seaman C, et al. Persistence and adherence to disease modifying drugs among patients with multiple sclerosis. Curr Med Res Opin 2010;26:663-74
11. Margolis JM, Fowler R, Johnson BH, et al. Disease-modifying drug initiation patterns in commercially insured multiple sclerosis patients: a retrospective cohort study. BMC Neurol 2011;11:122-31. http://www.biomedcentral. com/1471-2377/11/122. Accessed November 20, 2012.
12. Avasarala JR, O'Donovan CA, Roach SE, et al. Analysis of NAMCS data for multiple sclerosis, 1998-2004. BMC Med 2007;5.6 doi:10.1186/1741-7015-5-6 Accessed Jan 2013 http://www/biomedcentral.com/1741-7015/5/6
13. Vollmer TL, Hadjimichael O, Preiningerova J, et al. Disability and treatment patterns of multiple sclerosis patients in United States: a comparison of veterans and nonveterans. J Rehabil Res Dev 2002;39:163-74
14. Lo AC, Hadjimichael O, Vollmer TL. Treatment patterns of multiple sclerosis patients: a comparison of veterans and non-veterans using the NARCOMS registry. Mult Scler 2005;11:33-40
15. 104th Congress. Health Insurance Portability and Accountability Act of 1996. Public Law 104-191 ed. 1996.
16. Patti F. Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence. Patient Prefer Adherence 2010;4:1-9.
17. Mikol DD, Barkhof F, Coyle PK, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs. Glatiramer Acetate in Relapsing MS Disease [REGARD] Study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 2008;7: 903-14
18. O'Connor P, Filippi M, Arnason B, et al. 250 mg or 500 mg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol 2009;8: 889-97.
19. Gajofatto A, Bachetti P, Grimes B, et al. Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis. Mult Scler 2009;15:50-8